The new ePRO technology is said to improve patient compliance and enhance study setup by simplifying site tasks and reducing errors.

Biomedical Systems CEO Tim Barrett said: "The eCOA market is growing fast, and launching this technology enhances our ability to offer centralized diagnostic services.

"Our eCOA solutions will extend that prompt, reliable global service we’re known for to provide more reliable data while collecting data for primary and secondary endpoints."

The firm’s electronic clinical outcome assessment (eCOA) technology is used for clinical trials in around 40 countries for multiple therapeutic areas such as respiratory, gastrointestinal, dermatology, oncology and women’s health.

In addition, the company provides clinical trial solutions, including cardiac safety, pulmonary function, imaging, electronic and scientific affairs.